Global Non-Small Cell Lung Cancer Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Report ID: ARS12081 | Category: Healthcare | Pages: 110 | Format: PDF | Published Date: December 18,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3350.00 Multi User-$5700.00

Report Description
View Table of Contents

Report Summary

This report aims to provide a comprehensive presentation of the global market for Non-Small Cell Lung Cancer, with and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Small Cell Lung Cancer.

The Non-Small Cell Lung Cancer market size considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Non-Small Cell Lung Cancer market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Small Cell Lung Cancer manufacturers, new entrants, and industry chain related companies in this market with information for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

The global Non-Small Cell Lung Cancer market size in 2022 is 26948.4 million US dollars, and it is expected to be 67019.1 million US dollars by 2029, with a compound annual growth rate of 13.90% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:
The main players in the Non-Small Cell Lung Cancer market include F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), and Pfizer Inc. (U.S.). The share of the top 3 players in the Non-Small Cell Lung Cancer market is XX%.

REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of Non-Small Cell Lung Cancer market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:
The report segments the market by Type and Application. Single Drug Therapy accounted for XX% of Non-Small Cell Lung Cancer market in 2022. Combination Therapy share of XX%.
Hospitals accounted for XX% of the Non-Small Cell Lung Cancer market in 2022. Homecare accounts for XX%.

Chapter Outline
Chapter 1: Introduces the product overview, and global Non-Small Cell Lung Cancer market status and forecast by region.
Chapters 2-3: Segmented the global Non-Small Cell Lung Cancer market by type, and application. Analyze the revenue of market segments from different perspectives.
Chapter 4: Analysis of the competitive environment of Non-Small Cell Lung Cancer market participants. This mainly includes the revenue and market share of the top players, along with the players' M&A and expansion in recent years.
Chapters 5-9: Provide North America, Europe, Asia-Pacific, Latin America and Middle East & Africa Non-Small Cell Lung Cancer market country segmentation data.
Chapter 10: Analyzes the main companies in the Non-Small Cell Lung Cancer industry, including their main businesses, products/services, revenue, gross margin, and the latest developments.
Chapter 11: Introduces the market dynamics, the trends factors and drivers factors of the market, and the challenges and restraints faced by manufacturers in the industry.
Chapter 12: The main points and conclusions of the report.
Chapter 13: Concludes with an explanation of the data sources and research methods.

Highlights-Regions

North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia Pacific
China
Japan
South Korea
India
Southeast Asia
South America
Brazil
Argentina
Colombia
MEA
Saudi Arabia
Egypt
Nigeria

Player list
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GSK plc (U.K.)
Novartis AG (Switzerland)
Bayer AG (Germany)
Lilly (U.S.)
Merck & Co., Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India)
Lupin (India)
CLOVIS ONCOLOGY (U.S.)
Johnson & Johnson Private Limited (U.S.)

Types list
Single Drug Therapy
Combination Therapy

Application list
Hospitals
Homecare
Specialty Clinics
Others

Table of Content

1 Non-Small Cell Lung Cancer Market Overview
1.1 Non-Small Cell Lung Cancer Product Overview
1.1.1 Non-Small Cell Lung Cancer Product Scope
1.1.2 Non-Small Cell Lung Cancer Market Status and Outlook
1.2 Global Non-Small Cell Lung Cancer Market Size Overview by Region 2018 VS 2022VS 2029
1.3 Global Non-Small Cell Lung Cancer Market Size by Region (2018-2029)
1.4 Global Non-Small Cell Lung Cancer Historic Market Size by Region (2018-2023)
1.5 Global Non-Small Cell Lung Cancer Market Size Forecast by Region (2023-2029)
1.6 Key Regions, Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.1 North America Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.2 Europe Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.3 Asia-Pacific Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.4 Latin America Non-Small Cell Lung Cancer Market Size (2018-2029)
1.6.5 Middle East & Africa Non-Small Cell Lung Cancer Market Size (2018-2029)
2 Non-Small Cell Lung Cancer Market Overview by Type
2.3 Global Non-Small Cell Lung Cancer Market Size by Type: 2018 VS 2022 VS 2029
2.4 Global Non-Small Cell Lung Cancer Historic Market Size by Type (2018-2023)
2.5 Global Non-Small Cell Lung Cancer Forecasted Market Size by Type (2023-2029)
2.6 Key Regions Market Size Segment by Type (2018-2029)
2.6.1 North America Non-Small Cell Lung Cancer Market Size Breakdown by Type (2018-2029)
2.6.2 Europe Non-Small Cell Lung Cancer Market Size Breakdown by Type
2.6.3 Asia-Pacific Non-Small Cell Lung Cancer Market Size Breakdown by Type
2.6.4 Latin America Non-Small Cell Lung Cancer Market Size Breakdown by Type
2.6.5 Middle East and Africa Non-Small Cell Lung Cancer Market Size Breakdown by Type
3 Non-Small Cell Lung Cancer Market Overview by Application
3.3 Global Non-Small Cell Lung Cancer Market Size by Application: 2018 VS 2022 VS 2029
3.4 Global Non-Small Cell Lung Cancer Historic Market Size by Application (2018-2023)
3.5 Global Non-Small Cell Lung Cancer Forecasted Market Size by Application (2023-2029)
3.6 Key Regions Market Size Segment by Application (2018-2029)
3.6.1 North America Non-Small Cell Lung Cancer Market Size Breakdown by Application (2018-2029)
3.6.2 Europe Non-Small Cell Lung Cancer Market Size Breakdown by Application
3.6.3 Asia-Pacific Non-Small Cell Lung Cancer Market Size Breakdown by Application
3.6.4 Latin America Non-Small Cell Lung Cancer Market Size Breakdown by Application
3.6.5 Middle East and Africa Non-Small Cell Lung Cancer Market Size Breakdown by Application
4 Non-Small Cell Lung Cancer Competition Analysis by Players
4.1 Global Non-Small Cell Lung Cancer Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-Small Cell Lung Cancer as of 2022)
4.3 Date of Key Players Enter into Non-Small Cell Lung Cancer Market
4.4 Global Top Players Non-Small Cell Lung Cancer Headquarters and Area Served
4.5 Key Players Non-Small Cell Lung Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 Non-Small Cell Lung Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 North America Non-Small Cell Lung Cancer Market Segment by Country
5.1 North America Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
5.2 United States
5.3 Canada
6 Europe Non-Small Cell Lung Cancer Market Segment by Country
6.1 Europe Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
6.2 Germany
6.3 France
6.4 U.K.
6.5 Italy
6.6 Russia
6.7 Nordic
6.8 Rest of Europe
7 Asia-Pacific Non-Small Cell Lung Cancer Market Segment by Country
7.1 Asia-Pacific Non-Small Cell Lung Cancer Market Size by Region (2018-2029)
7.2 China
7.3 Japan
7.4 South Korea
7.5 Southeast Asia
7.6 India
7.7 Australia
7.8 Rest of Asia-Pacific
8 Latin America Non-Small Cell Lung Cancer Market Segment by Country
8.1 Latin America Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
8.2 Mexico
8.3 Brazil
8.4 Rest of Latin America
9 Middle East and Africa Non-Small Cell Lung Cancer Market Segment by Country
9.1 Middle East & Africa Non-Small Cell Lung Cancer Market Size by Country (2018-2029)
9.2 Turkey
9.3 Saudi Arabia
9.4 UAE
9.5 Rest of Middle East & Africa
10 Manufacturers Profiles
10.1  F. Hoffmann-La Roche Ltd. (Switzerland)
10.1.1 F. Hoffmann-La Roche Ltd. (Switzerland) Information
10.1.2 Business Overview
10.1.3 F. Hoffmann-La Roche Ltd. (Switzerland) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.1.4 Non-Small Cell Lung Cancer Products Offered
10.1.5 F. Hoffmann-La Roche Ltd. (Switzerland) Recent Development
10.2  Mylan N.V. (U.S.)
10.2.1 Mylan N.V. (U.S.) Information
10.2.2 Business Overview
10.2.3 Mylan N.V. (U.S.) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.2.4 Non-Small Cell Lung Cancer Products Offered
10.2.5 Mylan N.V. (U.S.) Recent Development
10.3  Teva Pharmaceutical Industries Ltd. (Israel)
10.3.1 Teva Pharmaceutical Industries Ltd. (Israel) Information
10.3.2 Business Overview
10.3.3 Teva Pharmaceutical Industries Ltd. (Israel) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.3.4 Non-Small Cell Lung Cancer Products Offered
10.3.5 Teva Pharmaceutical Industries Ltd. (Israel) Recent Development
10.4  Sanofi (France)
10.4.1 Sanofi (France) Information
10.4.2 Business Overview
10.4.3 Sanofi (France) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.4.4 Non-Small Cell Lung Cancer Products Offered
10.4.5 Sanofi (France) Recent Development
10.5  Pfizer Inc. (U.S.)
10.5.1 Pfizer Inc. (U.S.) Information
10.5.2 Business Overview
10.5.3 Pfizer Inc. (U.S.) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.5.4 Non-Small Cell Lung Cancer Products Offered
10.5.5 Pfizer Inc. (U.S.) Recent Development
10.6  GSK plc (U.K.)
10.6.1 GSK plc (U.K.) Information
10.6.2 Business Overview
10.6.3 GSK plc (U.K.) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.6.4 Non-Small Cell Lung Cancer Products Offered
10.6.5 GSK plc (U.K.) Recent Development
10.7  Novartis AG (Switzerland)
10.7.1 Novartis AG (Switzerland) Information
10.7.2 Business Overview
10.7.3 Novartis AG (Switzerland) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.7.4 Non-Small Cell Lung Cancer Products Offered
10.7.5 Novartis AG (Switzerland) Recent Development
10.8  Bayer AG (Germany)
10.8.1 Bayer AG (Germany) Information
10.8.2 Business Overview
10.8.3 Bayer AG (Germany) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.8.4 Non-Small Cell Lung Cancer Products Offered
10.8.5 Bayer AG (Germany) Recent Development
10.9  Lilly (U.S.)
10.9.1 Lilly (U.S.) Information
10.9.2 Business Overview
10.9.3 Lilly (U.S.) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.9.4 Non-Small Cell Lung Cancer Products Offered
10.9.5 Lilly (U.S.) Recent Development
10.10  Merck & Co., Inc. (U.S.)
10.10.1 Merck & Co., Inc. (U.S.) Information
10.10.2 Business Overview
10.10.3 Merck & Co., Inc. (U.S.) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.10.4 Non-Small Cell Lung Cancer Products Offered
10.10.5 Merck & Co., Inc. (U.S.) Recent Development
10.11  Sun Pharmaceutical Industries Ltd. (India)
10.11.1 Sun Pharmaceutical Industries Ltd. (India) Information
10.11.2 Business Overview
10.11.3 Sun Pharmaceutical Industries Ltd. (India) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.11.4 Non-Small Cell Lung Cancer Products Offered
10.11.5 Sun Pharmaceutical Industries Ltd. (India) Recent Development
10.12  Aurobindo Pharma (India)
10.12.1 Aurobindo Pharma (India) Information
10.12.2 Business Overview
10.12.3 Aurobindo Pharma (India) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.12.4 Non-Small Cell Lung Cancer Products Offered
10.12.5 Aurobindo Pharma (India) Recent Development
10.13  Lupin (India)
10.13.1 Lupin (India) Information
10.13.2 Business Overview
10.13.3 Lupin (India) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.13.4 Non-Small Cell Lung Cancer Products Offered
10.13.5 Lupin (India) Recent Development
10.14  CLOVIS ONCOLOGY (U.S.)
10.14.1 CLOVIS ONCOLOGY (U.S.) Information
10.14.2 Business Overview
10.14.3 CLOVIS ONCOLOGY (U.S.) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.14.4 Non-Small Cell Lung Cancer Products Offered
10.14.5 CLOVIS ONCOLOGY (U.S.) Recent Development
10.15  Johnson & Johnson Private Limited (U.S.)
10.15.1 Johnson & Johnson Private Limited (U.S.) Information
10.15.2 Business Overview
10.15.3 Johnson & Johnson Private Limited (U.S.) Non-Small Cell Lung Cancer Revenue, Gross Margin
10.15.4 Non-Small Cell Lung Cancer Products Offered
10.15.5 Johnson & Johnson Private Limited (U.S.) Recent Development
11 Non-Small Cell Lung Cancer Market Dynamics
11.1 Non-Small Cell Lung Cancer Industry Trends
11.2 Non-Small Cell Lung Cancer Growth Drivers
11.3 Non-Small Cell Lung Cancer Market Challenges
11.4 Non-Small Cell Lung Cancer Market Restraints
12 Research Findings and Conclusion
13 Methodology and Data Source
13.1 A Methodology
13.1.1 Research Process
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 B Data Source
13.2.1 Legal Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global Non-Small Cell Lung Cancer Market Report, History and Forecast 2018-2029, Breakdown Data by Companies, Key Regions, Types and Application

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?